VS-6766 + Defactinib for Cervical Cancers

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Stephenson Cancer Center, Oklahoma City, OK
Cervical Cancers+5 More
VS-6766 + defactinib - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or cervical cancer.

Eligible Conditions

  • Cervical Cancers
  • Mucinous Ovarian Cancer
  • Endometrioid Cancer
  • High Grade Serous Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 2 years

2 years
Disease Control Rate
Duration of Response
Incidence of Adverse Events
Overall Survival
Progression Free Survival
Proportion of Patients with objective response rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

VS-6766 + Defactinib
1 of 1
Experimental Treatment

55 Total Participants · 1 Treatment Group

Primary Treatment: VS-6766 + Defactinib · No Placebo Group · Phase 2

VS-6766 + Defactinib
Drug
Experimental Group · 1 Intervention: VS-6766 + defactinib · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Closest Location: Stephenson Cancer Center · Oklahoma City, OK
Photo of oklahoma city  1Photo of oklahoma city  2Photo of oklahoma city  3
2014First Recorded Clinical Trial
5 TrialsResearching Cervical Cancers
35 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are female and at least 18 years of age.\n
You have received at least one prior systemic therapy for metastatic disease
You have measurable disease according to RECIST 1.1.
You have a performance status of 1 or less.
The pathology material must be available prior to treatment assignment to be used for confirmation.
You have a tumor with known RAS mutation, BRAF (type I, II, and/or III) mutation, NF-1 and/or RAS activation status determined from previous NGS or molecular testing.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.